Provided by Tiger Fintech (Singapore) Pte. Ltd.

Unicycive Therapeutics, Inc.

0.6602
-0.0037-0.56%
Volume:342.70K
Turnover:230.86K
Market Cap:68.53M
PE:-1.35
High:0.6814
Open:0.6639
Low:0.6505
Close:0.6639
Loading ...

Company Profile

Company Name:
Unicycive Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
14
Office Location:
4300 El Camino Real,Suite 210,Los Altos,California,United States
Zip Code:
94022
Fax:
- -
Introduction:
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

Directors

Name
Position
Shalabh Gupta
Chief Executive Officer, President and Chairman of the Board
Brigitte Schiller
Director
John Ryan
Director
Sandeep Laumas
Director

Shareholders

Name
Position
Shalabh Gupta
Chief Executive Officer, President and Chairman of the Board
John Townsend
Chief Financial Officer
Pramod Gupta
Executive Vice President, Pharmaceutical and Business Operations